首页> 外文期刊>Molecules >Novel Benzothiazole, Benzimidazole and Benzoxazole Derivatives as Potential Antitumor Agents: Synthesis and Preliminary in Vitro Biological Evaluation
【24h】

Novel Benzothiazole, Benzimidazole and Benzoxazole Derivatives as Potential Antitumor Agents: Synthesis and Preliminary in Vitro Biological Evaluation

机译:新型苯并噻唑,苯并咪唑和苯并恶唑衍生物作为潜在的抗肿瘤药:合成及体外生物学初步评估

获取原文
           

摘要

In a previous hit-to-lead research program targeting anticancer agents, two promising lead compounds, 1a and 1b, were found. However, the poor solubility of 1a and 1b made difficult further in vivo studies. To solve this problem, a lead optimization was conducted through introducing N-methyl-piperazine groups at the 2-position and 6-position. To our delight, the optimized analogue 1d showed comparable antiproliferative activity in vitro with better solubility, compared with 1a. Based on this result, the replacement of the benzothiazole scaffold with benzimidazole and benzoxazole moieties afforded 1f and 1g, whose activities were fundamentally retained. In the preliminary in vitro biological evaluation, the immunofluorescence staining of HCT116 cells indicated that 1d, 1f and 1g led to cytosolic vacuolization which was not induced by 1a at low micromolecular concentrations. These results suggest that these optimized compounds might potentially constitute a novel class of anticancer agents, which merit further studies.
机译:在先前针对抗癌药的先导研究计划中,发现了两种有前途的先导化合物1a和1b。但是,1a和1b的溶解性差,使得进一步的体内研究变得困难。为了解决这个问题,通过在2-位和6-位引入N-甲基-哌嗪基团来进行前导优化。令我们高兴的是,与1a相比,优化的类似物1d在体外具有可比的抗增殖活性,且具有更好的溶解性。基于该结果,用苯并咪唑和苯并恶唑部分代替苯并噻唑支架得到1f和1g,其活性基本得以保留。在初步的体外生物学评估中,HCT116细胞的免疫荧光染色表明1d,1f和1g导致了胞质空泡化,而在低微分子浓度下1a则不会。这些结果表明,这些优化的化合物可能构成了新型的抗癌药物,值得进一步研究。

著录项

  • 来源
    《Molecules》 |2012年第1期|共11页
  • 作者

  • 作者单位
  • 收录信息
  • 原文格式 PDF
  • 正文语种
  • 中图分类 有机化学;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号